Tradipitant, also known as LY686017 or VLY-686, is being evaluated in clinical trials for the treatment of eczema, pruritus, idiopathic and diabetic gastroparesis, chronic pruritus, and atopic dermatitis, among others (1, 2, 3, 4). It has also been used in trials studying the treatment of alcohol dependence. Tradipitant is an orally bioavailable and brain penetrant NK-1 receptor antagonist that acts by blocking Substance P (SP) from acting on NK-1 receptors (NK-1R). SP and NK-1R are thought to regulate neurogenic inflammation and the pain perception pathway through the central nervous system. The activation of NK-1R by the natural ligand SP is thought to be involved in the perception of pain, behavioral stress response, cravings and nausea and vomiting signaling.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Tradipitant, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.